Canadian cannabis firm Hollister Biosciences entered into a definitive agreement to acquire Alphamind Brands, and closed the acquisition in April 2020. Alphamind are conducting R&D into psilocybin-based drug therapies, seeking to build an IP portfolio in the psychedelic medicine space. 

Market Performance

News & Interviews


Note: due to the emergent nature of the psychedelics sector, many publicly listed companies do not have complete valuation or financial data.